22.35 0.00 (0.00%)
After hours: 4:34PM EST
|Bid||19.60 x 800|
|Ask||22.63 x 1300|
|Day's Range||22.09 - 22.82|
|52 Week Range||12.70 - 25.07|
|Beta (3Y Monthly)||0.90|
|PE Ratio (TTM)||87.99|
|Earnings Date||Feb 12, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.83|
WASHINGTON , Nov. 8, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in November 2018 : The ...
Vanda stock flirted with a breakout Thursday after the biotech topped quarterly and profit expectations thanks largely to a sleeping-disorder drug.
Vanda (VNDA) delivered earnings and revenue surprises of 1900.00% and 0.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Washington-based company said it had profit of 13 cents. Earnings, adjusted for non-recurring costs, came to 20 cents per share. The results exceeded Wall Street expectations. ...
-- Hetlioz® net product sales grew to $29.9 million in the third quarter of 2018, a 34% increase compared to the third quarter of 2017 -- Results from clinical studies of tradipitant in gastroparesis and ...
D.C.-based Vanda Pharmaceuticals Inc. has updated its corporate website to address a FDA notice that a page online misbranded two of its drugs. But questions remain.
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Vanda Pharmaceuticals Inc (NASDAQ:VNDA) as an investment opportunity by taking the Read More...
WASHINGTON, Nov. 1, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (VNDA) today announced that it received a letter from the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion on October 22, 2018 regarding the content on a single page of its corporate website. To access the FDA letter, which was published on October 31, 2018, please refer to the FDA's website here. Vanda intends to meet with the FDA to better understand the reasoning of the letter.
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Vanda Pharmaceuticals is the IBD Stock Of The Day ahead of what Wall Street believes will be a fourth straight quarter of profitability.
Conference Call and Webcast to Follow WASHINGTON , Oct. 22, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter of 2018 ...
On October 3, Vanda Pharmaceuticals (VNDA) stock rose 2.42% to reach $22.84 from its October 2 close of $22.30. Vanda Pharmaceuticals’ October 3 stock price was up 92.0% from its 52-week low of $11.90 on November 13, 2017. Vanda Pharmaceuticals’ stock price reached $22.84 on October 3 from $15.30 at the open of the market on January 2, reflecting ~49.0% YTD (year-to-date) growth. Vanda Pharmaceuticals hit its 52-week high of $23.50 on September 26.
Insys Therapeutics’ (INSY) product pipeline includes cannabidiol oral solution and dronabinol inhalation. It also includes naloxone and epinephrine nasal sprays, buprenorphine and naloxone spray, and buprenorphine sublingual spray.
WASHINGTON , Sept. 26, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming 2018 investor conferences: The Oppenheimer ...
Stocks gave up all their gains and closed well in the red Wednesday, after the Federal Reserve hiked interest rates by a quarter-point, as widely expected.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 25) Abbott Laboratories (NYSE: ABT ) Amarin Corporation ...
NEW YORK , Sept. 25, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent Rollins Inc. (NYSE: ROL) ...
WASHINGTON , Sept. 20, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that a HETLIOZ ® patent, number 10,071,977 ('977 patent), is now listed in the U.S. Food and ...
Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Vanda Pharmaceuticals Inc (NASDAQ:VNDA) due to its excellent fundamentals in moreRead More...
WASHINGTON , Sept. 12, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results of a HETLIOZ ® (tasimelteon) driving study to measure next day performance. Tasimelteon ...
WASHINGTON , Sept. 4, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in September 2018 : ...